1. Home
  2. CORT vs CFR Comparison

CORT vs CFR Comparison

Compare CORT & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CORT
  • CFR
  • Stock Information
  • Founded
  • CORT 1998
  • CFR 1868
  • Country
  • CORT United States
  • CFR United States
  • Employees
  • CORT N/A
  • CFR N/A
  • Industry
  • CORT Biotechnology: Pharmaceutical Preparations
  • CFR Major Banks
  • Sector
  • CORT Health Care
  • CFR Finance
  • Exchange
  • CORT Nasdaq
  • CFR Nasdaq
  • Market Cap
  • CORT 8.8B
  • CFR 8.1B
  • IPO Year
  • CORT N/A
  • CFR N/A
  • Fundamental
  • Price
  • CORT $77.56
  • CFR $124.88
  • Analyst Decision
  • CORT Strong Buy
  • CFR Hold
  • Analyst Count
  • CORT 4
  • CFR 16
  • Target Price
  • CORT $139.00
  • CFR $138.38
  • AVG Volume (30 Days)
  • CORT 969.1K
  • CFR 369.3K
  • Earning Date
  • CORT 10-29-2025
  • CFR 10-30-2025
  • Dividend Yield
  • CORT N/A
  • CFR 3.27%
  • EPS Growth
  • CORT N/A
  • CFR 13.33
  • EPS
  • CORT 1.11
  • CFR 9.29
  • Revenue
  • CORT $716,080,000.00
  • CFR $2,079,741,000.00
  • Revenue This Year
  • CORT $30.77
  • CFR $13.47
  • Revenue Next Year
  • CORT $37.75
  • CFR $4.19
  • P/E Ratio
  • CORT $70.60
  • CFR $13.19
  • Revenue Growth
  • CORT 25.71
  • CFR 6.87
  • 52 Week Low
  • CORT $42.01
  • CFR $100.31
  • 52 Week High
  • CORT $117.33
  • CFR $147.64
  • Technical
  • Relative Strength Index (RSI)
  • CORT 47.10
  • CFR 47.65
  • Support Level
  • CORT $69.43
  • CFR $119.00
  • Resistance Level
  • CORT $80.29
  • CFR $125.76
  • Average True Range (ATR)
  • CORT 4.30
  • CFR 3.31
  • MACD
  • CORT -1.06
  • CFR -0.18
  • Stochastic Oscillator
  • CORT 38.77
  • CFR 56.57

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

About CFR Cullen/Frost Bankers Inc.

Cullen/Frost is a regional US bank with around $50 billion in assets (as of mid-2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.

Share on Social Networks: